We are currently facing a global health challenge regarding the
way we discover and develop new drugs. Small biotech companies,
as well as large pharmaceutical corporations, spend increasingly
more money on the classical route of drug development, and it fails
more often than it succeeds. Consequently, some diseases are not
being treated and patients who are in dire need of new therapies
are not receiving them.